Company Profile

Chrono Therapeutics Inc
Profile last edited on: 12/26/19      CAGE: 6JYX2      UEI: DFNAG1MWADP6

Business Identifier: Programmable, passive transdermal drug delivery systems to address a range of adddiction and neurological disorders
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3953 Point Eden Way
Hayward, CA 94545
   (917) 282-9768
Location: Single
Congr. District: 15
County: Alameda

Public Profile

With primary focus on those battling addictions and living with neurological disorders, Chrono Therapeutics is focused on improving clinical outcomes for patients battling addictions and living with neurological disorders using the firm's proprietary Digital Patch platform. Offering a new era of transdermal drug delivery designed to meet each patient's individual needs the efort is to integrate timed drug delivery with personalized, mobile-phone-based digital support and unique data analytics to maximize compliance. Outcome: to enable patients to manage hard to treat conditions and optimize clinical outcomes. With seeveral inplace programs in active development that address significant market opportunities with unmet (or poorly) met needs, the approach is to have each program leverages medications that readily cross the skin. In addition to the programs currently in development for smoking cessation, Parkinson's Disease dyskinesia and prescription opioid dependence, the firm's discovery pipeline is robust, with a number of CNS indications under evaluation that would benefit from a therapeutic combined with behavioral and compliance support

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 2 NIH $4,126,223
Project Title: Smartstop: Programmable Transdermal Nicotine Replacement Therapy
2017 2 NIH $2,155,317
Project Title: Tailored NRT Integrated with Smartphone Behavioral Support

Key People / Management

  Guy Dipierro -- Founder, Former Chief Business Officer, Senior Vice President

  Alan Levy -- CEO

  Kuo-Wei Chang -- Principal